Custom Antibody Market Overview and Growth by 2028

The custom antibody market was valued at US$ 833.71 million by 2028 from US$ 409.26 million in 2021; it is estimated to grow at a CAGR of 10.7% from 2021 to 2028.

Customized antibodies can be generated in a mouse, rat, or hamster, to meet any host requirements. Companies are providing wide range of antibodies according to the researcher's requirements. There are variety of customized antibodies in the market which includes polyclonal and monoclonal antibody, recombinant monoclonal antibody, hybridoma antibody, polyclonal recombinant antibody, and others. Companies are offering complete support services for all types and steps of antibody production from peptide design, synthesis, and carrier protein conjugation to animal immunization, serum collection, or hybridoma fusion, titer analysis, and final antibody purification.    

The growth of the custom antibody market is attributed to the factors such as the high demand in research, growing support from governments, continuously changing disease profiles, rising public–private partnerships, and increasing funding activities are widely enhancing the performance of biotechnology. However, the production for the monoclonal and polyclonal antibodies varies based on the animals being used to derive them. The cost is also determined by the packages of custom antibodies demanded for different applications that are offered by different players hinders the market growth.

Custom Antibody Market: Strategic Insights

Market Insights

Production and Development Services Offered by Custom Antibody Providers

Various companies are aggressively offering research and development services for custom antibodies. A few of such services launched in by these companies are mentioned below.

• In June 2021, GenScript announced the launch of its MonoRab, a custom rabbit monoclonal antibody (mAB) service. It is added in company’s integrated premium antibody service portfolio. MonoRab is the company’s proprietary technology that utilizes the combination of hybridoma technologies and early-stage monoclonal antibody sequencing. Both technologies delivers custom rabbit mAbs that are more specific and possess higher affinity as well as diversified abilities required for a broad range of applications.
• In March 2021, Giotto Biotech launched specialized polyclonal and monoclonal antibody production services. The company facilitates the production of more than 500 monoclonal antibody types that can be used for diagnostic and therapeutic applications. It offers a large choice of species as the sources of polyclonal antibodies.
• In November 2020, AMSBIO announced development services for rabbit and mouse recombinant monoclonal antibodies. The development of recombinant monoclonal antibodies is based on the DimAb development platform, which is different from conventional hybridoma fusion technologies. It has ability to isolate IgG genes from B cells of immunized animals. These antibodies assist in the development and commercialization of drugs in the market. In October 2019, the FDA approved first rabbit monoclonal antibody-derived drug—Beovu. Beovu is intended to treat wet age-related macular degeneration (AMD).
• In March 2020, Absolute Antibody Ltd announced the launch of high-throughput recombinant antibody production service for its FleXpress. The company offers its customers with services for facilitating the rapid expression of many antibodies, up to a volume of 80 ml scale, as well as for propelling the production capacity to meet rising demands for recombinant antibody technology.

Such custom antibody production services offered by companies are accelerating the market growth.

Service - Based Insights

Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, and antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, and is estimated to grow at significant CAGR during the forecast period.

Type-based Insights

Based on type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, and other custom antibodies. In 2020, the monoclonal antibodies segment held the largest share of the market, whereas the polyclonal antibodies segment is expected to grow during the forecast period.

Source -based Insights

Based on source, the custom antibody market is segmented into mice, rabbit, and others. The mice segment held the largest share of the market in 2020, whereas the mice segment is anticipated to register the highest CAGR in the market during the forecast period.

Research Area -based Insights

Based on research area, the custom antibody market is segmented into oncology, immunology, stem cells, infectious disease, neurobiology, cardiovascular disease, and others. The oncology segment held the largest share of the market in 2020, whereas the stem cells segment is anticipated to register the highest CAGR in the market during the forecast period.

End Users-based Insights

Based on end users, the custom antibody market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. In 2020, the pharmaceutical and biotechnology companies segment held the largest share of the market and is expected to grow at the fastest rate during the coming years.

Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the breast reconstruction market players focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.

The regional trends and factors influencing the Custom Antibody Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Custom Antibody Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Custom Antibody Market Report Scope

Custom Antibody Market Players Density: Understanding Its Impact on Business Dynamics

The Custom Antibody Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

By service

• Antibody Development
• Antibody Production and Purification
• Antibody Fragmentation and Labelling

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Custom Antibodies

By Source

• Mice
• Rabbits
• Others

By Research Area

• Oncology
• Immunology
• Stem Cells
• Infectious Diseases
• Neurobiology
• Cardiovascular Diseases
• Others

By End Users

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• Thermo Fisher Scientific Inc
• Bio-Rad Laboratories Inc 
• Merck KGaA
• ABCAM
• GenScript
• Rockland Immunochemicals, Inc
• ProMab
• BioLegend, Inc
• Agilent Technologies, Inc
• Cell Signaling Technology, Inc